2126 — JW (Cayman) Therapeutics Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$911.55m
- HK$637.78m
- CNY283.65m
Annual cashflow statement for JW (Cayman) Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -702 | -846 | -768 | -591 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 34.8 | 231 | 233 | 169 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 58.1 | -9.12 | 36.9 | -1.38 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -561 | -537 | -398 | -333 | — |
| Capital Expenditures | -137 | -101 | -14.6 | -15.4 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | -23.5 | 24.5 | 0 | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -137 | -124 | 9.9 | -15.4 | — |
| Financing Cash Flow Items | -18.3 | -6.79 | -12.4 | -12.2 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -30.6 | 112 | 0.275 | 90.5 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -796 | -451 | -377 | -249 | — |